Exploring the Use of Lebrikizumab (Ebglyss, Eli Lilly and Company) in AD Patients With Darker Skin Tones Featuring Dr. Andrew Alexis June 13, 2025
Clinical Trial Update: First Child Enrolled in Phase 2 Study of Roflumilast Cream, 0.05% (Zoryve, Arcutis) for Infants With AD June 10, 2025
Dupilumab (Dupixent, Sanofi & Regeneron) Performs Well in AD Patients With Darker Skin Tones June 9, 2025
Nemolizumab (Nemluvio, Galderma) Shows “Sustained and Increased” Improvements in Itch and Skin Lesions in AD Patients for Up to Two Years June 6, 2025
